Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Abbreviations AE: adverse events ADA: American Diabetes Association CI: confidence interval CKD: chronic kidney disease CV: cardiovascular CVD: cardiovascular disease ETD: estimated treatment difference GLP-1RA: glucagon-like peptide-1 receptor agonist HR: hazard ratio MACE: major adverse cardiac event MI: myocardial infarction T2D: type 2 diabetes References American Diabetes Association
Semaglutide and tirzepatide are injectable medications initially developed to treat Type 2 diabetes
A Different Approach From GLP-1 Drugs Unlike popular GLP-1 medications such as Ozempic, which are delivered by injection and work by influencing appetite signals between the gut and brain, the new treatment takes a completely different path
This pathway is a major focus of cutting-edge hair loss research
On June 24, 2026, Novo Nordisk, a global leader in diabetes and obesity treatments, officially launched its flagship weight-loss drug Wegovy (Semaglutide) in India
Understanding these mechanisms helps explain why the peptide shows such broad therapeutic potential
